Show simple item record

dc.contributor.advisorKarakayalı, Özlen Konu
dc.contributor.authorKeşküş, Ayşe Gökçe
dc.date.accessioned2021-10-07T06:44:57Z
dc.date.available2021-10-07T06:44:57Z
dc.date.copyright2021-09
dc.date.issued2021-09
dc.date.submitted2021-10-05
dc.identifier.urihttp://hdl.handle.net/11693/76589
dc.descriptionCataloged from PDF version of article.en_US
dc.descriptionThesis (Ph.D.): Bilkent University, Department of Neuroscience, İhsan Doğramacı Bilkent University, 2021.en_US
dc.descriptionIncludes bibliographical references (leaves 161-183).en_US
dc.description.abstractCholinergic receptor subunit alpha 5 (CHRNA5) is a ligand-gated ion channel expressed in not only the nervous system but also other tissues. Differential expression and the polymorphisms of CHRNA5 have been associated with addiction, particularly nicotine and various cancer types. The tumor-suppressive properties of CHRNA5 depletion, i.e., decrease in cell proliferation, induction of DNA damage response, and drug sensitivity, have been identified in breast cancer cell lines. This thesis focuses on identifying critical factors modulating or modulated by the knock-down of CHRNA5 in breast cancer cell lines using both wet-lab and bioinformatics approaches. Here I have first found the significant correlation between CHRNA5 and DNA damage response in breast cancer tumor datasets. Moreover, I discovered that the introduction of siTP53 antagonized the actions of siCHRNA5 and reverted the siCHRNA5-mediated cell cycle inhibition and drug sensitivity in the MCF7 breast cancer cell line. Furthermore, siCHRNA5 was found to inhibit the secondary signaling of estrogen/ESR1 in time and dosage-dependent manners. CHRNA5 depletion also downregulated the conserved 14q32.31 miRNA cluster expression. Among those miRNAs, miR495-3p appeared to be the most prominent candidate, exhibiting a similar expression profile with selective estrogen degraders and partially with siCHRNA5. However, the inhibitory effect of the combinatorial treatment with siCHRNA5 and miR495-3p on the secondary targets of estrogen signaling indicated that siCHRNA5 and miR495-3p might target converging pathways, evidenced by the antagonism (rather than addictiveness) between them. In addition, the Shiny-based syneRgy app was developed to analyze the transcriptome-based synergy between treatments and/or genetic modifications. As a case study, syneRgy analysis using novel MDM2 inhibitor and/or temozolomide treated neuroblastoma cell lines revealed that although the tumor-suppressor effect of combination therapy was more than each individual treatment, it was less than additive. syneRgy was applied to understand the combinatorial treatment of siCHRNA5 with siTP53 as well as siCHRNA5 with miR495-3p mimic and enhanced our understanding of the TFs that might have a role in the crosstalk. To our knowledge, syneRgy is the first-ever online tool to perform statistical synergy analysis using RNAseq count or logFC transcriptomic data and synreg, i.e. our novel methodology allowing for statistical tests of TF target enrichment using regression models.en_US
dc.description.statementofresponsibilityby Ayşe Gökçe Keşküşen_US
dc.format.extentxix, 186 leaves : illustrations (color), charts (color), graphics, tables ; 30 cm.en_US
dc.language.isoEnglishen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCHRNA5en_US
dc.subjectEstrogen signalingen_US
dc.subjectSelective estrogen receptor degradersen_US
dc.subjectSelective estrogen receptor modulatorsen_US
dc.subjectTP53 signalingen_US
dc.subjectmiRNAen_US
dc.subject14q31.32 miRNA clusteren_US
dc.subjectTranscriptomics, synergy analysisen_US
dc.titleIdentification of modulatory functions of TP53, estrogen signaling, and 14q32.31 miRNA cluster on CHRNA5 knock-down expression profile and development of syneRgy APPen_US
dc.title.alternativeTP53, östrojen sinyal yolağı, ve 14q32.31 miRNA grubu’nun CHRNA5 deplesyon ifade profili üzerine etkilerinin belirlenmesi ve syneRgy uygulamasının geliştirilmesien_US
dc.typeThesisen_US
dc.departmentInterdisciplinary Program in Neuroscience (NEUROSCIENCE)en_US
dc.publisherBilkent Universityen_US
dc.description.degreePh.D.en_US
dc.identifier.itemidB132987
dc.embargo.release2022-04-06


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record